Sugi Predict

Sugi Predict / Compounds / SCHEMBL16368596

SCHEMBL16368596

SCHEMBL16368596

CC(C)c1ccc(F)c(S(=O)(=O)NC(C)(C)C)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CNR1 P21554 2/20 0.45
▸ MAPT P10636 4/20 0.42
▸ LMNA P02545 2/20 0.42
▸ TP53 P04637 2/20 0.42
▸ KAT6A Q92794 1/20 0.41
▸ SMN1; SMN2 Q16637 4/20 0.39
▸ HPGD P15428 2/20 0.39
▸ KDM4E B2RXH2 1/20 0.39
▸ MEN1 O00255 1/20 0.39
▸ NPC1 O15118 1/20 0.39
▸ RAB9A P51151 1/20 0.39
▸ KMT2A Q03164 1/20 0.39
▸ ALDH1A1 P00352 4/20 0.39
▸ CYP3A4 P08684 1/20 0.39
▸ CYP2C9 P11712 1/20 0.39
▸ MAPK1 P28482 1/20 0.39
▸ PARG Q86W56 1/20 0.39
▸ POLB P06746 1/20 0.38
▸ HTT P42858 1/20 0.38
▸ TSHR P16473 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16259891 0.87 CNR1 (0.43) CNR1MAPTLMNAKAT6ASMN1; SMN2
SCHEMBL26144796 0.81 RNASEH1 (0.45) MAPTLMNATP53SMN1; SMN2HPGD
SCHEMBL24429345 0.80 ALDH1A1 (0.50) MAPTLMNAKAT6ASMN1; SMN2HPGD
SCHEMBL16259580 0.79 CNR1 (0.41) CNR1MAPTLMNASMN1; SMN2HPGD
SCHEMBL16259569 0.79 ALDH1A1 (0.41) CNR1MAPTLMNASMN1; SMN2HPGD
SCHEMBL13449501 0.78 ALDH1A1 (0.61) MAPTTP53SMN1; SMN2HPGDALDH1A1
SCHEMBL15723308 0.78 CNR1 (0.41) CNR1MAPTLMNAKAT6ASMN1; SMN2
SCHEMBL15723304 0.78 CNR1 (0.44) CNR1MAPTLMNASMN1; SMN2HPGD
SCHEMBL16849237 0.78 CNR1 (0.44) CNR1MAPTLMNAKAT6ASMN1; SMN2
SCHEMBL1790814 0.78 CNR1 (0.51) CNR1MAPTLMNASMN1; SMN2HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230147507-A1 INDOLINE COMPOUNDS FOR INHIBITING KIF18A VOLASTRA THERAPEUTICS, INC. (US) 2023-05-11 — — US disclosed
US-20230147507-A1 INDOLINE COMPOUNDS FOR INHIBITING KIF18A VOLASTRA THERAPEUTICS, INC. (US) 2023-05-11 — — US disclosed
US-9242975-B2 Heterocyclic-substituted pyridyl compounds useful as kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2016-01-26 — — US disclosed
US-8987311-B2 Triazolyl-substituted pyridyl compounds useful as kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2015-03-24 — — US disclosed
US-20150045347-A1 TRIAZOLYL-SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2015-02-12 — — US disclosed
US-20150011532-A1 HETEROCYCLIC-SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2015-01-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150045347-A1 TRIAZOLYL-SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS KINASE INHIBITORS IRAK4, IRAK3, IRAK1 CNR1 3742/4885MAPT 2020/4885LMNA 2436/4885
US-20150011532-A1 HETEROCYCLIC-SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS KINASE INHIBITORS IRAK4, IRAK1, IRAK2 CNR1 984/4885MAPT 2892/4885LMNA 1480/4885
US-20230147507-A1 INDOLINE COMPOUNDS FOR INHIBITING KIF18A KIF18A, KIF18B, KIF2C CNR1 4053/4885MAPT 151/4885LMNA 2893/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.